Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OB318 in Advanced Solid Malignancies
NCT02347228Phase 1Terminated
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OB318 in solid tumor, sponsored by Oneness Biotech Co., Ltd. Primary endpoints: Dose limiting toxicities at 28 days and Maximum tolerated dose at 28 days. Started Aug 2020; status: terminated.
02
Drugs
OB318
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02347228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347228.